Key result
FGF-2-modified MSCs improve functional recovery and reduce infarct volume after stroke compared with unmodified MSCs.
Answers are grounded in this paper and cite their sources.
BACKGROUND AND PURPOSE: Fibroblast growth factor-2 (FGF-2) administration and bone marrow stromal cell (MSC) transplantation could improve neurological deficits after occlusive cerebrovascular disease. In the present study, we examined the effects of neurological improvement after transient middle cerebral artery occlusion (MCAO) in rats by a novel therapeutic strategy with FGF-2 gene-transferred MSCs by the herpes simplex virus type 1 (HSV-1) vector. METHODS: Adult Wistar rats were anesthetized. Nonmodified MSCs, FGF-2-modified MSCs with HSV-1 1764/-4/pR19/ssIL2-FGF-2, or PBS was administered intracerebrally 24 hours after transient right MCAO. All animals underwent behavioral tests for 21 days, and the infarction volume with 2-3-5-triphenylterazolium was detected 3 days and 14 days after the MCAO. Three days and 7 days after the MCAO, the FGF-2 production in the ipsilateral hemisphere of the MCAO was measured with ELISA. Seven and 14 days after the MCAO, immunohistochemical staining for FGF-2 was applied. RESULTS: The stroke animals receiving FGF-2-modified MSCs demonstrated significant functional recovery compared with the other groups. Fourteen days after the MCAO, there was a significant reduction in infarction volume only in FGF-2-modified MSC-treated group. FGF-2 production in the FGF-2-modified MSC-treated brain was significantly higher compared with the other groups at 3 and 7 days after MCAO. Administrated FGF-2-modified MSCs strongly expressed the FGF-2 protein, which was proven by ELISA. CONCLUSIONS: Our data suggest that the FGF-2 gene-modified MSCs with the HSV-1 vector can contribute to remarkable functional recovery after stroke compared with MSCs transplantation alone.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2005) studied Transient focal cerebral ischemia (middle cerebral artery occlusion). FGF-2 gene-modified bone marrow stromal cells (MSCs) via HSV-1 vector vs. Nonmodified MSCs or PBS was evaluated on Neurological functional recovery and cerebral infarction volume. FGF-2-modified MSCs administered 24 hours post-stroke significantly improved functional recovery over 21 days and reduced infarction volume at 14 days compared with unmodified MSCs or PBS.
Synapse has enriched 10 related papers. Consider them for comparative context: